Herpes simplex virus drug resistance-HSV thymidine kinase mutants

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The widespread use of nucleoside analog antivirals to treat patients infected with herpes simplex virus (HSV) is indicted by the statement in a recent publication that, “More than 2.3 million kg of these drugs have been prescribed…in >30 countries” (1). Many clinical trials have demonstrated the effectiveness of these antivirals. However, clinical studies have also reported the detection of drugresistant viral mutants, particularly important in the care of immunosuppressed patients. Laboratory studies have indicated the mechanisms of viral resistance. The development of drug-resistant mutants of HSV has raised the issue of the potential pathogenicity of these mutants, and also mechanisms of HSV infection whereby such mutants may arise.

Original languageEnglish (US)
Title of host publicationEmerging Neurological Infections
PublisherCRC Press
Pages397-414
Number of pages18
ISBN (Electronic)9780849340871
ISBN (Print)9780824754235
StatePublished - Jan 1 2005

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Herpes simplex virus drug resistance-HSV thymidine kinase mutants'. Together they form a unique fingerprint.

  • Cite this

    Tenser, R. (2005). Herpes simplex virus drug resistance-HSV thymidine kinase mutants. In Emerging Neurological Infections (pp. 397-414). CRC Press.